SALT LAKE CITY, September 20, 2016 — Sera Prognostics, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Ladenburg Thalmann 2016 Healthcare Conference. Dr. Critchfield’s presentation will take place at 11:00 AM ET on Tuesday, September 27th, at the Sofitel Hotel in New York.

Sera Prognostics management will be available for one-on-one meetings with conference attendees during the day.  To schedule a meeting with management, please contact Andrew Sauter, Chief Financial Officer at

About Sera Prognostics, Inc.
Sera Prognostics, a women’s health company, develops innovative diagnostic tests focused on the early prediction of preterm birth (PTB) risk and other complications of pregnancy. Sera has launched its PreTRM® test, the first and only clinically validated blood test to accurately predict early in pregnancy the risk of premature birth. The test objectively reports to the physician the risk of premature delivery, enabling earlier proactive interventions designed to prolong gestation and improve neonatal health outcomes. Sera’s proprietary technology addresses both the health and economic challenges of PTB. Its strong management team has significant clinical development and women’s healthcare diagnostic experience. Sera is backed by highly respected healthcare investors, including Domain Associates, InterWest Partners, Catalyst Health Ventures, and the Bill & Melinda Gates Foundation. Currently, Sera is working with the Gates Foundation to translate the Company’s discoveries into alternative technologies ideal for low-income countries in its journey to improve maternal and infant health globally.  Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at

Company Contact:
Andrew Sauter, CFO
Sera Prognostics, Inc.
(801) 990-0772

Media Contact for Sera Prognostics
Terri Clevenger
Continuum Health Communications
(203) 856-4326